New combo therapy trial for tough liver cancers halted early
NCT ID NCT05171166
Summary
This study aimed to see if adding a specific type of chemotherapy directly into the liver's blood vessels (HAIC) before a standard artery-blocking treatment (TACE) and a targeted drug (donafenib) works better than just TACE plus the drug. It was for people with a specific advanced stage of liver cancer that cannot be removed by surgery. The trial was stopped early after enrolling only 18 of a planned 156 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.